Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 28,900 shares, a growth of 725.7% from the February 29th total of 3,500 shares. Based on an average trading volume of 91,700 shares, the days-to-cover ratio is currently 0.3 days. Currently, 5.5% of the shares of the company are sold short.

Aptevo Therapeutics Stock Performance

APVO opened at $4.69 on Friday. Aptevo Therapeutics has a fifty-two week low of $3.81 and a fifty-two week high of $92.62. The firm has a 50-day moving average of $6.08 and a 200 day moving average of $9.21.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP bought a new stake in shares of Aptevo Therapeutics in the 4th quarter worth approximately $29,000. Virtu Financial LLC purchased a new stake in Aptevo Therapeutics in the 2nd quarter worth about $46,000. Citadel Advisors LLC bought a new stake in Aptevo Therapeutics in the 4th quarter valued at about $47,000. Renaissance Technologies LLC raised its stake in Aptevo Therapeutics by 45.8% in the 2nd quarter. Renaissance Technologies LLC now owns 80,186 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 25,200 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in Aptevo Therapeutics during the first quarter valued at about $152,000. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Aptevo Therapeutics in a research report on Monday. They issued a “hold” rating on the stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.